NCT05459090 Functional Study of Inhibitory Neurotransmission in the Human Epileptic Brain.
| NCT ID | NCT05459090 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Neuromed IRCCS |
| Condition | Drug Resistant Epilepsy |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2022-07-29 |
| Primary Completion | 2025-02-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2022-07-29 with a primary completion date of 2025-02-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Epilepsy is a neurological condition that afflicts 1% of the world population. 30% of patients become drug-resistant to classic antiepileptic treatment and only a small percentage, 5%, can undergo a neurosurgical resection of epileptic focus and recover almost completely from symptoms. To date, an imbalance between inhibitory and excitatory neurotransmission has been well accepted as the main root cause of epilepsy. A better understanding of the molecular mechanisms of this can lead to developing new therapeutic strategies. The investigators of the project want to describe the functional alteration of GABA- A receptor, the main actor of inhibitory neurotransmission in the central nervous system and characterize its subunit composition in the epileptic foci of patients with temporal lobe epilepsy. The authors, also, want to modulate, by means of selective neuroactive molecules, the function of this receptor to increase the inhibitory tone in the epileptic brain.
Eligibility Criteria
Inclusion Criteria: Patients with drug-resistant temporal lobe epilepsy. Exclusion Criteria: * Patients suffering from Temporal lobe epilepsy caused by stroke, ischemia, cavernous angiomas, or meningiomas growth.
Contact & Investigator
katiuscia Martinello, Biology
PRINCIPAL INVESTIGATOR
Neuromed IRCCS
Frequently Asked Questions
Who can join the NCT05459090 clinical trial?
This trial is open to participants of all sexes, studying Drug Resistant Epilepsy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05459090 currently recruiting?
Yes, NCT05459090 is actively recruiting participants. Contact the research team at katiuscia.martinello@neuromed.it for enrollment information.
Where is the NCT05459090 trial being conducted?
This trial is being conducted at Pozzilli, Italy.
Who is sponsoring the NCT05459090 clinical trial?
NCT05459090 is sponsored by Neuromed IRCCS. The principal investigator is katiuscia Martinello, Biology at Neuromed IRCCS. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.